SCHEMBL23029003

SCHEMBL23029003

C=C(/C=C\N(C)C)NC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10465162 1.00 — —
SCHEMBL20853060 0.78 — —
SCHEMBL10465603 0.72 NPC1 (0.36) —
SCHEMBL21558183 0.72 TDP1 (0.39) —
SCHEMBL19343655 0.69 — —
SCHEMBL6518837 0.69 — —
SCHEMBL22142906 0.69 — —
SCHEMBL21894241 0.69 — —
SCHEMBL17080725 0.69 — —
SCHEMBL18903786 0.69 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
EP-3687506-B1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS BIOCRYST PHARM INC (US) 2021-07-07 — — EP disclosed
US-20210054466-A1 TUMOR BIOMARKERS AND USE THEREOF CUREGENIX CORPORATION 2021-02-25 — — US disclosed
Send feedback